{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:55:44Z","timestamp":1790736944638,"version":"4.1.0"},"reference-count":32,"publisher":"BMJ","issue":"e3","funder":[{"name":"JSPS KAKENHI","award":["JP20K17169"],"award-info":[{"award-number":["JP20K17169"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,4,12]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Morphine is effective in alleviating dyspnoea in patients with cancer. We aimed to investigate the effectiveness and safety of morphine administration for refractory dyspnoea in patients with advanced heart failure (HF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multicentre, prospective, observational study of hospitalised patients with advanced HF in whom morphine was administered for refractory dyspnoea. Morphine effectiveness was evaluated by dyspnoea intensity changes, assessed regularly by both a quantitative subjective scale (Visual Analogue Scale (VAS; graded from 0 to 100 mm)) and an objective scale (Support Team Assessment Schedule\u2014Japanese (STAS-J; graded from 0 to 4 points)). Safety was assessed by vital sign changes and new-onset severe adverse events, including nausea, vomiting, constipation and delirium based on the Common Terminology Criteria for Adverse Events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 15 Japanese institutions between September 2020 and August 2022, we included 28 hospitalised patients with advanced HF in whom morphine was administered (mean age: 83.8\u00b18.7 years, male: 15 (54%), New York Heart Association class IV: 26 (93%) and mean left ventricular ejection fraction: 38%\u00b119%). Both VAS and STAS-J significantly improved from baseline to day 1 (VAS: 67\u00b126 to 50\u00b131 mm; p=0.02 and STAS-J: 3.3\u00b10.8 to 2.6\u00b11.1 points; p=0.006, respectively), and thereafter the improvements sustained through to day 7. After morphine administration, vital signs including blood pressure, pulse rate and oxygen saturation did not change, and no new-onset severe adverse events occurred through to day 7.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study suggested acceptable effectiveness and safety for morphine administration in treating refractory dyspnoea in hospitalised patients with advanced HF.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2023-004247","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:20:21Z","timestamp":1683825621000},"page":"e1300-e1307","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness and safety of morphine administration for refractory dyspnoea among hospitalised patients with advanced heart failure: the Morphine-HF study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-7424","authenticated-orcid":false,"given":"Yasuhiro","family":"Hamatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Anchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Inuzuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibiki","family":"Mima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoe","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Korai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2024051713532282000_13.e3.e1300.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035858"},{"key":"2024051713532282000_13.e3.e1300.2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1253\/circj.CJ-20-1127","article-title":"JCS\/JHFS 2021 statement on palliative care in cardiovascular diseases","volume":"85","author":"Anzai","year":"2021","journal-title":"Circ J"},{"key":"2024051713532282000_13.e3.e1300.3","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ehf2.13907","article-title":"Comprehensive symptom assessment using integrated palliative care outcome scale in hospitalized heart failure patients","volume":"9","author":"Hamatani","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024051713532282000_13.e3.e1300.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-5151(03)00059-8"},{"key":"2024051713532282000_13.e3.e1300.5","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008337624200"},{"key":"2024051713532282000_13.e3.e1300.6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/jpm.2016.0145","article-title":"Treatment recommendations for respiratory symptoms in cancer patients: clinical guidelines from the Japanese Society for palliative medicine","volume":"19","author":"Yamaguchi","year":"2016","journal-title":"J Palliat Med"},{"key":"2024051713532282000_13.e3.e1300.7","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"2024051713532282000_13.e3.e1300.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2024051713532282000_13.e3.e1300.9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10354-009-0726-0","article-title":"Opioids for symptomatic therapy of dyspnoea in patients with advanced chronic heart failure -- is there evidence?","volume":"159","author":"Hochgerner","year":"2009","journal-title":"Wien Med Wochenschr"},{"key":"2024051713532282000_13.e3.e1300.10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jjcc.2019.12.015","article-title":"Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients","volume":"75","author":"Kawaguchi","year":"2020","journal-title":"J Cardiol"},{"key":"2024051713532282000_13.e3.e1300.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197112232852601"},{"key":"2024051713532282000_13.e3.e1300.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"2024051713532282000_13.e3.e1300.13","first-page":"623","article-title":"New grading of level of disordered consiousness (author\u2019s transl)","volume":"2","author":"Ohta","year":"1974","journal-title":"No Shinkei Geka"},{"key":"2024051713532282000_13.e3.e1300.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-5299.2004.03475.x"},{"key":"2024051713532282000_13.e3.e1300.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.01.011"},{"key":"2024051713532282000_13.e3.e1300.16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0468"},{"key":"2024051713532282000_13.e3.e1300.17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1017\/S1478951504040507","article-title":"Reliability and validity of the Japanese version of the support team assessment schedule (STAS-J)","volume":"2","author":"Miyashita","year":"2004","journal-title":"Palliat Support Care"},{"key":"2024051713532282000_13.e3.e1300.18","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s00520-019-05081-9","article-title":"How successful are we in relieving terminal dyspnea in cancer patients? A real-world multicenter prospective observational study","volume":"28","author":"Mori","year":"2020","journal-title":"Support Care Cancer"},{"key":"2024051713532282000_13.e3.e1300.19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"2024051713532282000_13.e3.e1300.20","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1089\/jpm.2018.0272","article-title":"Morphine for refractory dyspnea in interstitial lung disease: a phase I study (JORTC-PAL 05)","volume":"21","author":"Matsuda","year":"2018","journal-title":"J Palliat Med"},{"key":"2024051713532282000_13.e3.e1300.21","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1680"},{"key":"2024051713532282000_13.e3.e1300.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.523"},{"key":"2024051713532282000_13.e3.e1300.23","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.11.939"},{"key":"2024051713532282000_13.e3.e1300.24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2169\/internalmedicine.55.5362","article-title":"Continuous intravenous morphine infusion for severe dyspnea in terminally ill interstitial pneumonia patients","volume":"55","author":"Takeyasu","year":"2016","journal-title":"Intern Med"},{"key":"2024051713532282000_13.e3.e1300.25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1253\/circj.CJ-17-1305","article-title":"Nationwide survey of palliative care for patients with heart failure in Japan","volume":"82","author":"Kuragaichi","year":"2018","journal-title":"Circ J"},{"key":"2024051713532282000_13.e3.e1300.26","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309102520"},{"key":"2024051713532282000_13.e3.e1300.27","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1001\/jama.2022.20206","article-title":"Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the beams randomized clinical trial","volume":"328","author":"Ekstr\u00f6m","year":"2022","journal-title":"JAMA"},{"key":"2024051713532282000_13.e3.e1300.28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/1049909119832816","article-title":"Opioids for relief of dyspnea immediately before death in patients with noncancer disease: a case series study","volume":"36","author":"Murakami","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"2024051713532282000_13.e3.e1300.29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-021-00281-4","article-title":"Adverse drug reactions in Japanese patients with end-stage heart failure receiving continuous morphine infusion: a single-center retrospective cohort study","volume":"9","author":"Gotou","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2024051713532282000_13.e3.e1300.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18472"},{"key":"2024051713532282000_13.e3.e1300.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-001929"},{"key":"2024051713532282000_13.e3.e1300.32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvz200","article-title":"Palliative care for people living with heart failure: European association for palliative care Task force expert position statement","volume":"116","author":"Sobanski","year":"2020","journal-title":"Cardiovasc Res"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2023-004247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:50:13Z","timestamp":1715989813000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2023-004247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":32,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2023-004247"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2023-004247","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}